Cargando…

Cardiac and noncardiac biomarkers in patients undergoing anthracycline chemotherapy – a prospective analysis

BACKGROUND: Biomarkers represent a potential tool to identify individuals at risk for anthracycline-induced cardiotoxicity (AICT) prior to symptom onset or left ventricular dysfunction. METHODS: This study examined the levels of cardiac and noncardiac biomarkers before, after the last dose of, and 3...

Descripción completa

Detalles Bibliográficos
Autores principales: Dean, Matthew, Kim, Min Jung, Dimauro, Sharon, Tannenbaum, Susan, Graham, Garth, Liang, Bruce T., Kim, Agnes S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133897/
https://www.ncbi.nlm.nih.gov/pubmed/37106424
http://dx.doi.org/10.1186/s40959-023-00174-1
_version_ 1785031655922073600
author Dean, Matthew
Kim, Min Jung
Dimauro, Sharon
Tannenbaum, Susan
Graham, Garth
Liang, Bruce T.
Kim, Agnes S.
author_facet Dean, Matthew
Kim, Min Jung
Dimauro, Sharon
Tannenbaum, Susan
Graham, Garth
Liang, Bruce T.
Kim, Agnes S.
author_sort Dean, Matthew
collection PubMed
description BACKGROUND: Biomarkers represent a potential tool to identify individuals at risk for anthracycline-induced cardiotoxicity (AICT) prior to symptom onset or left ventricular dysfunction. METHODS: This study examined the levels of cardiac and noncardiac biomarkers before, after the last dose of, and 3–6 months after completion of doxorubicin chemotherapy. Cardiac biomarkers included 5th generation high-sensitivity cardiac troponin T (cTnT), N-terminal pro-brain natriuretic peptide, growth/differentiation factor-15 (GDF-15), and soluble suppression of tumorigenesis-2 (sST2). Noncardiac biomarkers included activated caspase-1 (CASP-1), activated caspase-3, C-reactive protein, tumor necrosis factor-α, myeloperoxidase (MPO), galectin-3, and 8-hydroxy-2’-deoxyguanosine. Echocardiographic data (LVEF and LVGLS) were obtained at pre- and post-chemotherapy. Subanalysis examined interval changes in biomarkers among high (cumulative doxorubicin dose ≥ 250 mg/m(2)) and low exposure groups. RESULTS: The cardiac biomarkers cTnT, GDF-15, and sST2 and the noncardiac biomarkers CASP-1 and MPO demonstrated significant changes over time. cTnT and GDF-15 levels increased after anthracycline exposure, while CASP-1 and MPO decreased significantly. Subanalysis by cumulative dose did not demonstrate a larger increase in any biomarker in the high-dose group. CONCLUSIONS: The results identify biomarkers with significant interval changes in response to anthracycline therapy. Further research is needed to understand the clinical utility of these novel biomarkers. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40959-023-00174-1.
format Online
Article
Text
id pubmed-10133897
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101338972023-04-28 Cardiac and noncardiac biomarkers in patients undergoing anthracycline chemotherapy – a prospective analysis Dean, Matthew Kim, Min Jung Dimauro, Sharon Tannenbaum, Susan Graham, Garth Liang, Bruce T. Kim, Agnes S. Cardiooncology Research BACKGROUND: Biomarkers represent a potential tool to identify individuals at risk for anthracycline-induced cardiotoxicity (AICT) prior to symptom onset or left ventricular dysfunction. METHODS: This study examined the levels of cardiac and noncardiac biomarkers before, after the last dose of, and 3–6 months after completion of doxorubicin chemotherapy. Cardiac biomarkers included 5th generation high-sensitivity cardiac troponin T (cTnT), N-terminal pro-brain natriuretic peptide, growth/differentiation factor-15 (GDF-15), and soluble suppression of tumorigenesis-2 (sST2). Noncardiac biomarkers included activated caspase-1 (CASP-1), activated caspase-3, C-reactive protein, tumor necrosis factor-α, myeloperoxidase (MPO), galectin-3, and 8-hydroxy-2’-deoxyguanosine. Echocardiographic data (LVEF and LVGLS) were obtained at pre- and post-chemotherapy. Subanalysis examined interval changes in biomarkers among high (cumulative doxorubicin dose ≥ 250 mg/m(2)) and low exposure groups. RESULTS: The cardiac biomarkers cTnT, GDF-15, and sST2 and the noncardiac biomarkers CASP-1 and MPO demonstrated significant changes over time. cTnT and GDF-15 levels increased after anthracycline exposure, while CASP-1 and MPO decreased significantly. Subanalysis by cumulative dose did not demonstrate a larger increase in any biomarker in the high-dose group. CONCLUSIONS: The results identify biomarkers with significant interval changes in response to anthracycline therapy. Further research is needed to understand the clinical utility of these novel biomarkers. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40959-023-00174-1. BioMed Central 2023-04-27 /pmc/articles/PMC10133897/ /pubmed/37106424 http://dx.doi.org/10.1186/s40959-023-00174-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Dean, Matthew
Kim, Min Jung
Dimauro, Sharon
Tannenbaum, Susan
Graham, Garth
Liang, Bruce T.
Kim, Agnes S.
Cardiac and noncardiac biomarkers in patients undergoing anthracycline chemotherapy – a prospective analysis
title Cardiac and noncardiac biomarkers in patients undergoing anthracycline chemotherapy – a prospective analysis
title_full Cardiac and noncardiac biomarkers in patients undergoing anthracycline chemotherapy – a prospective analysis
title_fullStr Cardiac and noncardiac biomarkers in patients undergoing anthracycline chemotherapy – a prospective analysis
title_full_unstemmed Cardiac and noncardiac biomarkers in patients undergoing anthracycline chemotherapy – a prospective analysis
title_short Cardiac and noncardiac biomarkers in patients undergoing anthracycline chemotherapy – a prospective analysis
title_sort cardiac and noncardiac biomarkers in patients undergoing anthracycline chemotherapy – a prospective analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133897/
https://www.ncbi.nlm.nih.gov/pubmed/37106424
http://dx.doi.org/10.1186/s40959-023-00174-1
work_keys_str_mv AT deanmatthew cardiacandnoncardiacbiomarkersinpatientsundergoinganthracyclinechemotherapyaprospectiveanalysis
AT kimminjung cardiacandnoncardiacbiomarkersinpatientsundergoinganthracyclinechemotherapyaprospectiveanalysis
AT dimaurosharon cardiacandnoncardiacbiomarkersinpatientsundergoinganthracyclinechemotherapyaprospectiveanalysis
AT tannenbaumsusan cardiacandnoncardiacbiomarkersinpatientsundergoinganthracyclinechemotherapyaprospectiveanalysis
AT grahamgarth cardiacandnoncardiacbiomarkersinpatientsundergoinganthracyclinechemotherapyaprospectiveanalysis
AT liangbrucet cardiacandnoncardiacbiomarkersinpatientsundergoinganthracyclinechemotherapyaprospectiveanalysis
AT kimagness cardiacandnoncardiacbiomarkersinpatientsundergoinganthracyclinechemotherapyaprospectiveanalysis